- Patients who were assigned to an axitinib (AG-013736) containing treatment arm in a
previous clinical trial
- Patients who were receiving axitinib (AG-013736) tablets at the time their previous
trial ended
- Patients who have stable (SD) or responding disease (PR or CR) documented by the
appropriate radiological, clinical, or laboratory assessments within 12 weeks before
enrollment (Note: response criteria from the previous axitinib (AG-013736) protocol
should be used to determine stable or responding disease).
- Patients who have progressive disease (PD) but have experienced "clinical benefit" as
defined in the study protocol
- Patients may not participate in this trial if the conditions for continuing treatment
in the previous axitinib (AG-013736) protocol are not met